Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
For second time Sandoz faces claims it is trying to reap benefits of biosimilars law without meeting its obligations.